Evidence map›Paper›PMID 38920742›Full record

SynthesisCurrent oncology (Toronto, Ont.)2024

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Elodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel, François Bocquet, Olivier Bouché, Anthony Turpin, Thomas Aparicio, Jean-Louis Legoux, Laetitia Dahan, Julien Taieb and 6 more

Abstract readSystematic Review
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elodie MartinInstitut de Cancérologie de l'Ouest, F 49055 Angers, France.ORCID 0000-0003-0821-8971
Karine Le MalicotFédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, University of Burgundy, F 21078 Dijon, France.ORCID 0000-0002-3226-8525
Catherine Guérin-CharbonnelInstitut de Cancérologie de l'Ouest, F 49055 Angers, France.ORCID 0000-0001-7493-4314
François BocquetInstitut de Cancérologie de l'Ouest, F 49055 Angers, France.
Olivier BouchéDepartment of Digestive Oncology, CHU Reims, F 51092 Reims, France.ORCID 0000-0002-8284-3743
Anthony TurpinDepartment of Medical Oncology, University Hospital, F 59000 Lille, France.ORCID 0000-0002-2282-0101
Thomas AparicioDepartment of Gastroenterology, Saint Louis Hospital, APHP, Université Paris Cité, F 75010 Paris, France.ORCID 0000-0001-8834-6927
Jean-Louis LegouxDepartment of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Régional, F 45100 Orléans, France.
Laetitia DahanC.H.U. la Timone and Université de la Méditerranée Marseille, F 13005 Marseille, France.
Julien TaiebInstitut du Cancer Paris CARPEM, Gastroenterology and Digestive Oncology Department, APHP Centre-Université Paris Cité, Hôpital Européen G. Pompidou, F 75015 Paris, France.
Côme LepageDepartment of HGE & Digestive Oncology, EPICAD INSERM UMR LNC 1231, University Hospital Dijon, University of Burgundy, F 21078 Dijon, France.ORCID 0000-0001-9211-4707
Louis-Marie DourtheService d'Oncologie Médicale, Clinique St Anne, F 67000 Strasbourg, France.
Caroline PétorinService d'Oncologie Digestive, CHU Clermont-Ferrand, F 63000 Clermont-Ferrand, France.
Vincent BourgeoisService d'Oncologie Digestive, Centre Hospitalier de Boulogne sur Mer, F 62321 Boulogne-sur-Mer, France.
Jean-Luc RaoulInstitut de Cancérologie de l'Ouest, F 49055 Angers, France.ORCID 0000-0001-6305-8953
Valérie SeegersInstitut de Cancérologie de l'Ouest, F 49055 Angers, France.ORCID 0000-0003-1404-0292

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In controlled phase II trials, major prognostic factors need to be well balanced between arms. The main procedures used are SPBR (Stratified Permuted Block Randomization) and minimization. First, we provide a systematic review of the treatment allocation procedure used in gastrointestinal oncology controlled phase II trials published in 2019. Second, we performed simulations using data from six phase II studies to measure the impacts of imbalances and bias on the efficacy estimations. From the 40 articles analyzed, all mentioned randomization in both the title and abstract, the median number of patients included was 109, and 77.5% were multicenter. Of the 27 studies that reported at least one stratification variable, 10 included the center as a stratification variable, 10 used minimization, 9 used SBR, and 8 were unspecified. In real data studies, the imbalance increased with the number of centers. The total and marginal imbalances were higher with SBR than with minimization, and the difference increased with the number of centers. The efficiency estimates per arm were close to the original trial estimate in both procedures. Minimization is often used in cases of numerous centers and guarantees better similarity between arms for stratification variables for total and marginal imbalances in phase II trials.

Indexed as

Clinical Trials, Phase II as TopicDigestive System NeoplasmsGastrointestinal NeoplasmsHumansPrognosisRandomized Controlled Trials as TopicResearch Designminimizationphase II trialsrandomization

Identifiers

PMID38920742
PMCPMC11202503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.